Haemonetics Corp at JPMorgan Healthcare Conference Transcript
Hi, everyone. My name is Rohin Patel. I'm a med tech analyst at J.P. Morgan. It's my pleasure to have Haemonetics here with us. And I'd like to introduce CEO, Chris Simon, for a presentation.
Thanks, Rohin, and thank you to J.P. Morgan for hosting the conference and giving us an opportunity to discuss our strategy and plans for long-term shareholder value creation. Thank you all for joining, both here in the room and on the WebEx.
First point, just a necessary disclosure. Remarks will include some forward-looking statements and some non-GAAP numbers. So the usual safe harbor and risk factors apply. Please see our SEC filings for additional details.
If I step back and try to share with you Haemonetics at a glance, the way I would articulate it is that we're the global leader in plasma apheresis. We see that as a $1 billion addressable market growing at least in the mid-single digits. It provides a highly durable
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
